Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

926027

Sigma-Aldrich

NanoFabTX-DOTAP Lipid Mix

for synthesis of cationic (DOTAP) liposomes

Synonyme(s) :

Drug delivery, LNP, Microfluidics, NanoFab reagent kit, Nanoformulation, Nanoparticle

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Code UNSPSC :
12162002
Nomenclature NACRES :
NA.23

Niveau de qualité

Température de stockage

−20°C

Description générale

NanoFabTx-DOTAP Lipid Mix includes reagents and optimized protocols with step-by-step instructions for synthesizing cationic liposomes for drug delivery research applications. The modification of liposomes with the cationic lipid, DOTAP, have numerous advantages such as their large-DNA incorporation, high transfection efficiency, and low toxicity. Liposome-based formulations are widely used for drug delivery applications and enable improved therapeutic efficacy of a range of drug types including small molecules, nucleic acids, proteins, and peptides.

Comprehensive protocols for liposome synthesis are included:

  • A lipid film hydration and extrusion protocol.
  • A microfluidics protocol using commercial platforms or syringe pumps.

The microfluidics protocol included with this product uses NanoFabTx device kits (911593). These kits come with the microfluidics chips, fittings, and tubing required to get started with microfluidics-based synthesis (compatible microfluidics system or syringe pump required).

Application

NanoFabTx-DOTAP Lipid Mix is a ready-to-use nanoformulation blend for the synthesis of cationic DOTAP-functionalized liposomes. This kit enables users to encapsulate a wide variety of therapeutic drug molecules for targeted or extended drug delivery without the need for lengthy trial-and-error optimization. NanoFabTx kits provide an easy-to-use toolkit for encapsulating a variety of therapeutics in nanoparticles, microparticles, or liposomes. Drug encapsulated particles synthesized with the NanoFabTx kits are suitable for biomedical research applications such as oncology, immuno-oncology, gene delivery, and vaccine delivery.

Caractéristiques et avantages

  • A ready-to-use nanoformulation blend for the synthesis of cationic liposomes
  • Step-by-step protocols (extrusion or microfluidic) developed and tested by our formulation scientists
  • Flexible synthesis tools to create uniform and reproducible liposomes
  • Optimized to make liposomes around 100 nm with low polydispersity
  • DOTAP surface-functionalized allows for targeting ligand conjugation to enable targeted drug delivery

Informations légales

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Which polymers can make nanoparticulate drug carriers long-circulating?
Torchilin VP, et al.
Advanced Drug Delivery Reviews, 16, 141-155 (1995)
Which polymers can make nanoparticulate drug carriers long-circulating?
Torchilin V P, et al.
Advanced Drug Delivery Reviews, 16, 141-155 (1995)
Yunes Panahi et al.
Artificial cells, nanomedicine, and biotechnology, 45(4), 788-799 (2017-03-11)
Liposome is a new nanostructure for the encapsulation and delivery of bioactive agents. There are a lot of bioactive materials that could be incorporated into liposomes including cosmetics, food ingredients, and pharmaceuticals. Liposomes possess particular properties such as biocompatibility, biodegradability;
T D Madden et al.
Chemistry and physics of lipids, 53(1), 37-46 (1990-03-01)
We have shown previously that transmembrane proton gradients can be used to efficiently accumulate biogenic amines [M.B. Bally et al. (1988) Chem. Phys. Lipids 47, 97-107] and doxorubicin [L.D. Mayer, M.B. Bally and P.R. Cullis (1986) Biochim. Biophys. Acta 857
D Papahadjopoulos et al.
Proceedings of the National Academy of Sciences of the United States of America, 88(24), 11460-11464 (1991-12-15)
The results obtained in this study establish that liposome formulations incorporating a synthetic polyethylene glycol-derivatized phospholipid have a pronounced effect on liposome tissue distribution and can produce a large increase in the pharmacological efficacy of encapsulated antitumor drugs. This effect

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique